RGNX

7.90

14.00% 0.97

Vorhandelsmarkt: 7.92 0.02 +0.25%

Regenxbio Inc (RGNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.93

Offen:

$7.18

24-Stunden-Volumen:

4.81M

Relative Volume:

3.98

Marktkapitalisierung:

$408.41M

Einnahmen:

$170.44M

Nettoeinkommen (Verlust:

$-193.88M

KGV:

-2.1044

EPS:

-3.7541

Netto-Cashflow:

$-126.38M

1W Leistung:

+28.87%

1M Leistung:

+38.11%

6M Leistung:

-40.02%

1J Leistung:

-8.78%

1-Tages-Spanne:

$7.18

$8.73

1-Wochen-Bereich:

$5.88

$8.73

52-Wochen-Spanne:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Firmenname

Regenxbio Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

240-552-8181

Adresse

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Mitarbeiter

371

Twitter

@REGENXBIO

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RGNX Regenxbio Inc	7.90	365.50M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-02-11	Herabstufung	Goldman	Buy → Neutral
2025-02-07	Fortgesetzt	Raymond James	Outperform
2024-11-15	Fortgesetzt	Morgan Stanley	Overweight
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-06-07	Eingeleitet	Goldman	Buy
2024-03-11	Eingeleitet	H.C. Wainwright	Buy
2024-03-08	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-03-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-21	Fortgesetzt	Raymond James	Outperform
2023-11-01	Eingeleitet	Stifel	Buy
2023-06-02	Eingeleitet	Robert W. Baird	Outperform
2022-06-23	Eingeleitet	Berenberg	Buy
2021-12-15	Eingeleitet	Wedbush	Neutral
2021-10-19	Fortgesetzt	Morgan Stanley	Overweight
2021-01-06	Hochstufung	Raymond James	Outperform → Strong Buy
2020-12-16	Eingeleitet	UBS	Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-08-20	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Bestätigt	Chardan Capital Markets	Buy
2019-06-14	Fortgesetzt	Raymond James	Outperform
2019-06-05	Bestätigt	Chardan Capital Markets	Buy
2019-02-25	Hochstufung	Evercore ISI	In-line → Outperform
2019-02-05	Hochstufung	Raymond James	Outperform → Strong Buy
2018-12-17	Bestätigt	Chardan Capital Markets	Buy
2018-11-08	Bestätigt	BofA/Merrill	Neutral
2018-08-08	Bestätigt	Chardan Capital Markets	Buy
2018-07-23	Herabstufung	BofA/Merrill	Buy → Neutral
2018-07-10	Bestätigt	Chardan Capital Markets	Buy
2018-05-09	Bestätigt	Barclays	Overweight
2018-04-09	Bestätigt	Chardan Capital Markets	Buy
2018-03-12	Herabstufung	Evercore ISI	Outperform → In-line
2018-02-13	Eingeleitet	Mizuho	Neutral
2017-11-09	Fortgesetzt	Morgan Stanley	Overweight

Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

Jun 15, 2026

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - Eastern Progress

Jun 15, 2026

Jun 14, 2026

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress

Jun 14, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Jun 14, 2026

Jun 11, 2026

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com

Jun 11, 2026

Jun 08, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo

Jun 08, 2026

H.C. Wainwright lowers Regenxbio stock price target on trial data By Investing.com - Investing.com South Africa

Jun 08, 2026

H.C. Wainwright lowers Regenxbio stock price target on trial data - Investing.com

Jun 08, 2026

Jun 06, 2026

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail

Jun 06, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Jun 05, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo

Jun 05, 2026

RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Lowered to $26 - GuruFocus

Jun 05, 2026

Regenxbio slides after late-stage trial data for Duchenne therapy - MSN

Jun 05, 2026

Jun 04, 2026

JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A - Stock Titan

Jun 04, 2026

Jun 03, 2026

REGENXBIO (RGNX) offers exchange of 2.9M eligible options for replacements - Stock Titan

Jun 03, 2026

REGENXBIO (NASDAQ: RGNX) investors back board, reject executive option swap - Stock Titan

Jun 03, 2026

Jun 02, 2026

REGENXBIO (RGNX) awards director Daniel Tasse RSUs and options - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director receives new RSU and stock option awards - Stock Titan

Jun 02, 2026

[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options - Stock Titan

Jun 02, 2026

REGENXBIO (RGNX) director awarded 9,807 RSUs and 46,600 stock options - Stock Titan

Jun 02, 2026

Director at REGENXBIO (RGNX) receives RSU and option grants - Stock Titan

Jun 02, 2026